What is the role of interleukin 10 in polymicrobial sepsis: Anti- inflammatory agent or immunosuppressant?

Surgery

Volumn 126, Issue 2, 1999, Pages 378-383

  Song, Grace Y ^a   Chung, Chun Shiang ^a   Chaudry, Irshad H ^a   Ayala, Alfred ^a,b  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 10; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDOTOXEMIA; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SPLEEN CELL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032853454     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(99)70180-7     Document Type: Article

References (25)

1. 1. Goris RJA, Sepsis and multiple organ failure: the result of whole body inflammation. In: Faist E, Meakins J, Schildberg FW, editors. Host defense dysfunction in trauma, shock and sepsis. Berlin: Springer-Verlag; 1993. p 161-70.
2. 2. Mannick JA, Trauma, sepsis and immune defects. In: Faist E, Meakins JL, Schildberg FW, editors. Host defense dysfunction in trauma, shock and sepsis. Berlin: Springer-Verlag; 1993. p 15-21.
3. 3. Howard M, O'Garra A, Ishida H, Malefyt RD, DeVries J. Biological properties of interleukin 10. J Clin Immunol 1992;12:239-47.
4. 4. Selzman CH, Shames BD, Miller SA, Pulido EJ, Meng X, McIntyre RC Jr, et al. Therapeutic implications of interleukin-10 in surgical disease. Shock 1998;10:309-18.
5. 5. Ayala A, Deol ZK, Lehman DL, Herdon CD, Chaudry IH. Polymicrobial sepsis but not low dose endotoxin infusion causes decreased splenocyte IL-2/IFN-gamma release while increasing IL-4/IL-10 production. J Surg Res 1994;56:579-85.
6. 6. O'Sullivan ST, Lederer JA, Horgan AF, Chin DHL, Mannick JA, Rodrick ML. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg 1995;222:482-92.
7. 7. Ayala A, Lehman DL, Herdon CD, Chaudry IH. Mechanism of enhanced susceptibility to sepsis following hemorrhage: interleukin (IL)-10 suppression of T-cell response is mediated by eicosanoid induced IL-4 release. Arch Surg 1994;129:1172-8.
8. 8. Kelly JL, Lyons A, Soberg CC, Mannick JA, Lederer JA. Anti-interleukin-10 antibody restores burn-induced defects in T-cell function. Surgery 1997;122:146-52.
9. 9. Mack VE, McCarter MD, Naama HA, Calvano SE, Daly JM. Dominance of T-helper 2-type cytokines after severe injury. Arch Surg 1996;131:1303-9.
10. 10. Neidhardt R, Jeel M, Steckholzer U, Safret A, Ungethuem U, Trentz O, et al. Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. J Trauma 1997;42:863-71.
11. 11. Lyons A, Kelly JL, Rodrick ML, Mannick JA, Lederer JA. Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection. Ann Surg 1997;226:450-60.
12. 12. Bermudez LE, Champsi J. Infection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice. Infect Immun 1993;61:3093-7.
13. 13. Rogy MA, Auffenberg T, Espat NJ, Philip R, Remick D, Wollenberg GK, et al. Human tumor necrosis factor receptor (p55) and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuates local inflammatory responses. J Exp Med 1995;181:2289-93.
14. 14. Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock - a review of laboratory models and a proposal. J Surg Res 1980;29:189-201.
15. 15. Kisala JM, Ayala A, Perrin MM, Stephan RN. Lethality and altered macrophage cytokine production following sepsis in endotoxin-tolerant mice. Circ Shock 1989;27:304.
16. 16. Ayala A, Perrin MM, Kisala JM, Ertel W, Chaudry IH. Polymicrobial sepsis selectively activates peritoneal but not alveolar macrophage to release inflammatory mediators (IL-1, IL-6 and TNF). Circ Shock 1992;36:191-9.
17. 17. Meldrum DR, Ayala A, Perrin MM, Ertel W, Chaudry IH. Diltiazem restores IL-2, IL-3, IL-6 and IFN-gamma synthesis and decreases susceptibility to sepsis following hemorrhage. J Surg Res 1991;51:158-64.
18. 18. Remick DG, Garg SJ, Newcomb DE, Wollenberg G, Huie TK, Bolgos GL. Exogenous interleukin-10 fails to decrease the mortality or morbidity of sepsis. Crit Care Med 1998;26:895-904.
19. 19. Ertel W, Keel M, Steckholzer U, Ungethūm U, Trentz O. Interleukin-10 attenuates the release of proinflammatory cytokines but depresses splenocyte functions in murine endotoxemia. Arch Surg 1996;131:51-6.
20. 20. Song GY, Chung CS, Chaudry IH, Ayala A. Does necrotic tissue depress cell-mediated immune function in polymicrobial sepsis? Surg Forum 1998;49:22-3.
21. 21. Steinhauser ML, Hogaboam CM, Kunkel SL, Lukacs NW, Strieter RM, Standiford TJ. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 1999;162:392-9.
22. 22. Van der Poll T, Marchant A, Buurman W, Berman L, Keogh CV, Lazarus KK, et al. Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol 1995;155:5397-401.
23. 23. Rennick DM, Fort MM, Davidson NJ. Studies with IL-10 -/-mice: an overview. J Leukocyte Biol 1997;61:389-96.
24. 24. Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 1992;148:2724-30.
25. 25. Remick D, Manohar P, Bolgos G, Rodriguez J, Moldawer L, Wollenberg G. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 1995;4:89-95.